# Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases

> **NCT07745257** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 40 (estimated)

## Conditions studied

- HR-positive, HER2-negative Metastatic Breast Cancer With Brain Metastases

## Interventions

- **DRUG:** Culmerciclib
- **DRUG:** Anlotinib
- **DRUG:** Endocrine Therapy

## Key facts

- **NCT ID:** NCT07745257
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-28
- **Primary completion:** 2027-12-28
- **Final completion:** 2028-07-28
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07745257

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07745257, "Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07745257. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*